Technology research; Telemedicine and connected care.
Issues related to reimbursement for diabetic retinopathy.
Duration: October 1, 2015
to
February 28, 2021
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Veterans , Budget/Appropriations , Telecommunications
Spending: about $2,150,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), U.S. Senate, House of Representatives, Homeland Security - Dept of (DHS), Treasury - Dept of
Affiliated organizations: Welch Allyn
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Katherine Getty Intrn, Rep Rigell, May-Oct 2014
Kendall Hussey Sen Health Labor Pension Comm, 05-08
Heide Bajnrauh Intrn, Sen McCain, 94-96; LSA, 96-97
Jeff McMillen Staff dir, H Ways & Means Subcomm on Sel Rev Measures, Mar 01-Mar 04; staff, H Ways & Means Subcom on Oversight, Jun 98-Mar 01
Martie Kendrick n/a
Eli Tomar n/a
Beth Collins n/a
Louis Agnello n/a
Hunter Bates n/a
Todd Tuten n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2021
AKIN GUMP STRAUSS HAUER & FELD terminated an engagement in which they represented Hill-Rom on April 20, 2021.
Original Filing: 301263069.xml
Lobbying Issues
Technology research; Telemedicine and connected care.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to reimbursement for diabetic retinopathy.
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2020
In Q4, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240627.xml
Lobbying Issues
Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).; COVID-19 health care legislative and regulatory implementation and funding issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748) and the HEROES Act (H.R. 6800), Consolidated Appropriations Act, 2021 (H.R. 133)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).; COVID-19 health care legislative and regulatory implementation and funding issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748) and the HEROES Act (H.R. 6800), Consolidated Appropriations Act, 2021 (H.R. 133)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Sec. S965 and GILTI.; COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748) the HEROES Act (H.R. 6800), Consolidated Appropriations Act, 2021 (H.R. 133)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221246.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).; COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748); and the HEROES Act (H.R. 6800)Technology research.
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the COVID-19 health care issues issues within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Telemedicine and connected care; Remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); The implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); Safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).; COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the COVID-19 health care issues issues within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748); the HEROES Act (H.R. 6800)
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Sec. S965 and GILTI.; the HEROES Act (H.R. 6800).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on July 19, 2020.
Original Filing: 301194311.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the COVID-19 health care issues issues within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Telemedicine and connected care; Remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); The implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); Safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Sec. S965 and GILTI.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $130,000. The report was filed on April 19, 2020.
Original Filing: 301173182.xml
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the COVID-19 health care issues issues within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Telemedicine and connected care; Remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); The implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); Safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
Agencies Lobbied
U.S. Senate
Lobbying Issues
COVID-19 tax issues including, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Sec. S965 and GILTI.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $130,000. The report was filed on Jan. 20, 2020.
Original Filing: 301123469.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2019 (H.R. 2207/S. 692); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018. Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 2207, S.692); taxation of medical technology; Further Consolidated Appropriations Act, 2020, (H.R.1865).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $140,000. The report was filed on Oct. 20, 2019.
Original Filing: 301072835.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2019 (H.R. 2207/S. 692); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018. Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 2207, S.692); taxation of medical technology.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $140,000. The report was filed on July 22, 2019.
Original Filing: 301058733.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2019 (H.R. 2207/S. 692); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018. Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 (H.R. 2740); Sepsis funding and education.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 2207, S.692); taxation of medical technology.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $150,000. The report was filed on April 22, 2019.
Original Filing: 301038221.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act
(H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (S. 692, H.R. 2207); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe
patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2019 (H.R. 2207/S. 692); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 2207, S.692); taxation of medical technology.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $160,000. The report was filed on Jan. 22, 2019.
Original Filing: 301014257.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 184/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018; H.R.6639 Diabetic Retinopothy Vision Loss and Blindness Prevention Act of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, H.R.6639 Diabetic retinopothy Vision Loss and Blindness Prevention Act of 2018; Extension of Continuing Appropriations Act of 2018; Bipartisan Budget Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 184); taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $250,000. The report was filed on Oct. 22, 2018.
Original Filing: 300996836.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018; H.R.6639 Diabetic Retinopothy Vision Loss and Blindness Prevention Act of 2018
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, H.R.6639 Diabetic retinopothy Vision Loss and Blindness Prevention Act of 2018; Extension of Continuing Appropriations Act of 2018; Bipartisan Budget Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 184); taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
Health & Human Services - Dept of (HHS)
2nd Quarter, 2018
In Q2, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $130,000. The report was filed on July 20, 2018.
Original Filing: 300978691.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, diabetic retinopathy; Extension of Continuing Appropriations Act of 2018; Bipartisan Budget Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal (H.R. 184); taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
Health & Human Services - Dept of (HHS)
1st Quarter, 2018
In Q1, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $130,000. The report was filed on April 20, 2018.
Original Filing: 300953016.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; Bipartisan Budget Act of 2018; safe patient handling, FDA reform; Extension of Continuing Appropriations Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, diabetic retinopathy; Extension of Continuing Appropriations Act of 2018; Bipartisan Budget Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal; taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
Health & Human Services - Dept of (HHS)
4th Quarter, 2017
In Q4, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $90,000. The report was filed on Jan. 19, 2018.
Original Filing: 300928338.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; the American Health Care Act (H.R. 1628)/Better Care Reconciliation Act; safe patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, diabetic retinopathy, American Health Care Act (H.R. 1628)/Better Care Reconciliation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal; taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
Health & Human Services - Dept of (HHS)
3rd Quarter, 2017
In Q3, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914916.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; the American Health Care Act (H.R. 1628)/Better Care Reconciliation Act; safe patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, diabetic retinopathy, American Health Care Act (H.R. 1628)/Better Care Reconciliation Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal; taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
Health & Human Services - Dept of (HHS)
2nd Quarter, 2017
In Q2, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on July 19, 2017.
Original Filing: 300888603.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; the American Health Care Act (H.R. 1628); safe patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, diabetic retinopathy, American HealthCare Act (H.R. 1628).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal; taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
Health & Human Services - Dept of (HHS)
1st Quarter, 2017
In Q1, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on April 19, 2017.
Original Filing: 300871514.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 1041/S. 108); the implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); diabetic retinopathy; the American Health Care Act (H.R. 1628); safe patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 184/S. 108); the implementation of the Medicare Access and CHIP reauthorization Act (H.R. 2); safe patient handling, FDA reform, diabetic retinopathy, American HealthCare Act (H.R. 1628).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal; taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
VA Procurement and payment reforms; prompt pay, veterans choice program issues, Care Veterans Deserve Act (H.R. 1152).
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on Jan. 19, 2017.
Original Filing: 300849822.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 160/S. 149); 21st Century Cures Act (H.R. 6/HR 34); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642); safe patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642); safe patient handling, FDA reform.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical Device excise tax repeal; taxation of medical technology; R & D tax credit; corporate tax reform.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $70,000. The report was filed on Oct. 20, 2016.
Original Filing: 300836841.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 160/S. 149); 21st Century Cures Act (H.R. 6); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); H.R. 160/S. 149; implementation of S. 3187, the Food and Drug Administration Safety and Innovation Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300820593.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 160/S. 149); 21st Century Cures Act (H.R. 6); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442); Diabetic Eye Disease Prevention Act (H.R. 4642).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); H.R. 160/S. 149; implementation of S. 3187, the Food and Drug Administration Safety and Innovation Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300796497.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 160/S. 149); 21st Century Cures Act (H.R. 6); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948); CONNECT for Health Act (S 2484/HR 4442).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); H.R. 160/S. 149; implementation of S. 3187, the Food and Drug Administration Safety and Innovation Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, AKIN GUMP STRAUSS HAUER & FELD lobbied for Hill-Rom , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300783452.xml
Lobbying Issues
Technology research; telemedicine and connected care; remote patient monitoring; community health centers and school health; implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); the Protect Medical Innovation Act (H.R. 160/S. 149); accountable care organizations; 21st Century Cures Act (H.R. 6); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical device tax; implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); telemedicine and connected care; remote patient monitoring; Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); Protect Medical Innovation Act of 2015 (H.R. 160/S. 149); The Medicare Access and CHIP Reauthorization Act (H.R. 2); Medicare Telehealth Parity Act (H.R. 2948)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medical device tax; IC-DISC; implementation of Patient Protection and Affordable Care Act (H.R. 3590/Pub. L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/Pub. L. 111-152); H.R. 160/S. 149; FY 2016 budget; implementation of S. 3187, the Food and Drug Administration Safety and Innovation Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
AKIN GUMP STRAUSS HAUER & FELD filed a lobbying registration on Nov. 18, 2015 to represent Hill-Rom, effective Oct. 1, 2015.
Original Filing: 300767817.xml
Issue(s) they said they’d lobby about: Telehealth, remote patient monitoring, telemedicine, medical device tax repeal .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...